<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="145">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04497272</url>
  </required_header>
  <id_info>
    <org_study_id>20-PP-18</org_study_id>
    <nct_id>NCT04497272</nct_id>
  </id_info>
  <brief_title>Assesment of the Metabolomic Signature in COVID-19 Patients</brief_title>
  <acronym>SignCov</acronym>
  <official_title>Assesment of the Metabolomic Signature in COVID-19 Patients (SignCov Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Metabolomics is the analysis of small molecules in a biological sample (cells, tissues or&#xD;
      biological fluids). It can potentially detect very sensitively any change related to a&#xD;
      pathology or exposure to a toxic agent. The analyses are fast, inexpensive and therefore&#xD;
      applicable in routine, particularly in health care. Given the emergence of this new disease,&#xD;
      COVID-19, there is a real need to better understand the pathophysiological mechanisms of&#xD;
      SARS-CoV-2 infection. In this context, metabolomics could have a place and could lead to the&#xD;
      development of interesting diagnostic or prognostic tools. The objective of this study is to&#xD;
      identify, through the analysis of biological samples (blood and urine), whether there is a&#xD;
      metabolomic signature in patients with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 7, 2020</start_date>
  <completion_date type="Anticipated">October 7, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 7, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Patient with COVID-19 disease</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Identifying the metabolomic signature</measure>
    <time_frame>Enrollment</time_frame>
    <description>To dentified a metabolomic profile using liquid chromatography combined with mass spectrometry (LC-MS) on the serum and urine of COVID-19 patients</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of the metabolomic profile according to clinical severity.</measure>
    <time_frame>Enrollment</time_frame>
    <description>Identification of the metabolomic profile of patients infected with SARS CoV 2 in the following subgroups: pauci-symptomatic patients, symptomatic patients without clinical severity criteria, and critically ill COVID-19 patients.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>COVID 19</condition>
  <arm_group>
    <arm_group_label>The metabolomic signature of COVID-19 patients</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>COVID-19 patients</intervention_name>
    <description>It will consist in the collection of 1 additional tubes at their blood draw and 1 urine sample.</description>
    <arm_group_label>The metabolomic signature of COVID-19 patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patient over 18 years of age&#xD;
&#xD;
          -  affiliated to a social security scheme&#xD;
&#xD;
          -  consultant in the emergency department and/or being hospitalized for suspected SARS&#xD;
             CoV infection&#xD;
&#xD;
          -  confirmation, after medical examination, of the need for a biological examination&#xD;
             (this will negate the need for additional venipuncture)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patient who do not meet inclusion criteria&#xD;
&#xD;
          -  Person subject to a guardianship order&#xD;
&#xD;
          -  Opposition to the use of the data or samples (withdrawal of non-opposition) /&#xD;
             Sponsor's or investigator's decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>OCCELLI Céline</last_name>
    <role>Principal Investigator</role>
    <affiliation>Néphrologie, CHU de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>OCCELLI Céline</last_name>
    <phone>+33492033204</phone>
    <email>occelli.c@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de nice</name>
      <address>
        <city>Nice</city>
        <state>Alpes-Maritimes</state>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>OCCELLI Céline</last_name>
      <phone>+33492033204</phone>
      <email>occelli.c@chu-nice.fr</email>
    </contact>
    <investigator>
      <last_name>OCELLI Celine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 3, 2020</study_first_submitted>
  <study_first_submitted_qc>August 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 4, 2020</study_first_posted>
  <last_update_submitted>November 6, 2020</last_update_submitted>
  <last_update_submitted_qc>November 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

